drugset

drugset / Trial / NCT02771301

Safety and Efficacy of IDH1R132H-DC Vaccine in Gliomas

NCT02771301 ↗

Unknown 30 enrolled Hebei Yanda Hospital Beijing Tiantan Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

This trial is aimed at evaluating the safety and efficacy of IDH1R132H-DC vaccine in glioma with IDH1R132H mutation.

Timeline

Start: 2016-02
Primary completion: 2019-01
Completion: 2019-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dendritic cells	Cell therapy	—	Subcutaneous

Indications